CAPR

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Capricor Therapeutics, Inc. (CAPR) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) A (4.2) C (2.2) C (2.5) A+ (5.0) B (3.3)
2026-11-10 C+ (2.5) D+ (1.8) C (2.3) B- (2.9) A+ (5.0) B- (2.9)
2026-11-03 C+ (2.5) D+ (1.8) C (2.3) B- (3.0) A+ (5.0) B- (2.9)
2026-10-27 C+ (2.5) D+ (1.8) C (2.4) C- (2.1) D (1.4) C- (2.0)
2026-10-20 C+ (2.5) D+ (1.8) C (2.4) D (1.4) D (1.5) C- (1.9)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe